- Advanced search
- Immuno Portal
- Malaria Portal
hydralazine is an approved drug (FDA (1953))
Compound class: Synthetic organic
Comment: Hydralazine is a hydrazinophthalazine class anti-hypertensiove drug.
Hydralazine is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Used to treat hypertension and severe congestive cardiac failure.|
|Mechanism Of Action and Pharmacodynamic Effects|
|The molecular mechanism of action of this drug has not been fully resolved, but appears to involve vasodilatory action which improves cardiac oxygenation and reduces its workload. See the DrugBank link for further details.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)